GEN Exclusives

More »

GEN News Highlights

More »
May 4, 2012

Qiagen Buys AmniSure for Noninvasive Fetal Membrane Rupture Assay

  • Qiagen has bought AmniSure International for the Boston-based firm’s marketed AmniSure® assay for detecting rupture of fetal membranes (ROM) in pregnancy. About 30% of pregnant women are currently assessed for ROM, a condition in which amniotic fluid leaks from the amniotic sac prematurely, commonly leading to maternal and neonatal infections, as well as premature birth.

    The point-of-need AmniSure test comprises a one-step, minimally invasive test strip that can detect amniotic fluid in vaginal discharge within minutes. “This accurate diagnostic test contributes significant value in the management of pregnancy and adds to Qiagen’s portfolio of tests, in particular for the ob/gyn market,” comments Peer Schatz, CEO.

    AmniSure will operate as a wholly owned subsidiary of Qiagen. Acquisition of the business will add about $12 million to Qiagen’s sales sheet in 2012, and an expected $24 million in 2013. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?